Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer

REFERENCES

• Cannobio L., Boccardo F., Pastorino G., , et al. Phase II Study of Navelbine in Advanced Breast Cancer. Semin. Oncol. 1989; 16: 33–36
   PubMed Web of Science ®Google Scholar
• Fumoleau P., Delgado F.M., Delozier T., , et al. Phase II Trial of Weekly Intravenous Vinorelbine in First Line Advanced Breast Cancer Chemotherapy. J. Clin. Oncol. 1993; 11: 1245–1252
   PubMed Web of Science ®Google Scholar
• Garcia-Conde J., Lluch A., Martijn M., , et al. Phase II Trial of Weekly IV Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy. Ann. Oncol. 1994; 5: 854–857
   PubMed Web of Science ®Google Scholar
• Romero A., Rabinovich M.G., Vallejo C.T., , et al. Vinorelbine as First-Line Chemotherapy for Metastatic Breast Carcinoma. J. Clin. Oncol. 1994; 12: 336–341
   PubMed Web of Science ®Google Scholar
• Weber B.L., Vogel C., Jones S., , et al. Intravenous Vinorelbine as First-Line and Second-Line Therapy in Advanced Breast Cancer. J. Clin. Oncol. 1995; 13: 2722–2730
   PubMed Web of Science ®Google Scholar
• Bruno S., Puerto V.L., Mickiewicz E., , et al. Phase II Trial of Weekly IV Vinorelbine as a Single Agent in First-Line Advanced Breast Cancer Chemotherapy: The Latin-American Experience. Am. J. Clin. Oncol. 1995; 18: 392–396
   PubMed Web of Science ®Google Scholar
• Twelves C.J., Dobbs N.A., Curnow A., , et al. A Phase II Multicentre UK Study of Vinorelbine in Advanced Breast Cancer. Br. J. Cancer 1994; 70: 990–993
   PubMed Web of Science ®Google Scholar
• Extra J.-M., Leandri S., Dieras V., , et al. Phase II Study of Vinorelbine in First and Second Line Treatment of Advanced Breast Cancer. Navelbine (Vinorelbine) Update and New Trends, P. Solal Celigny. John Libbey Eurotext, Montrouge 1991
   Google Scholar
• Tresca P., Fumoleau P., Roche H., , et al. Vinorelbine, An Active New Drug in Breast Carcinoma: Results of an ARTAC Phase II Trial. Proc. 13th Ann. San Antonio Breast Cancer Symp. 1990; 16: A66
   Google Scholar
• Gasparini G., Caffo O., Barni S., , et al. Vinorelbine is an Active Anti-Proliferative Agent in Pre-treated Advanced Breast Cancer Patients: A Phase II Study. J. Clin. Oncol. 1994; 12: 2094–2101
   PubMed Web of Science ®Google Scholar
• Degardin M., Bonneterre J., Hecquet B., , et al. Vinorelbine (Navelbine) as a Salvage Treatment for Advanced Breast Cancer. Ann. Oncol. 1994; 5: 423–426
   PubMed Web of Science ®Google Scholar
• Demicheli R., Terenziani M., Ferrari M., , et al. Activity of Vinorelbine in Advanced Breast Cancer: Preliminary Results of a Phase II Trial. Eur. J. Cancer 1993; 29A(Suppl. 6)A446
   Google Scholar
• Dogliotti L., Gorzegno G., Bau M.G., , et al. Vinorelbine as a Second Line Treatment in Anthracycline Pre-Treated Advanced Breast Cancer Patients: A Phase II Study. Eur. J. Cancer 1993; 29A: A430
   Google Scholar
• Fernandez O., Dodyk P., Fernandez L., , et al. Salvage Chemotherapy with Vinorelbine in Advanced Breast Cancer. Proc. 5th Int. Cong. Anti-Cancer Chemother. 1995; 231: AP379
   Google Scholar
• Nistico C., Ranuzzi M., Pace A., , et al. Weekly Vinorelbine in Previously Treated Patients with Advanced Breast Cancer: Preliminary Results. Proc. Am. Soc. Clin. Oncol. 1995; 14: A181
   Google Scholar
• Chevallier B., Fumoleau P., Kerbrat P., , et al. Docetaxel is a Major Cytotoxic Drug for the Treatment of Advanced Breast Cancer: A Phase II Trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 1995; 13: 314–322
   PubMed Web of Science ®Google Scholar
• Dieras V., Chevallier B., Kerbrat P., , et al. A Multicentre Phase II Study of Docetaxel 75 mg/m2 as First-line Chemotherapy for Patients with Advanced Breast Cancer: Report of the Clinical Screening Group of the EORTC. Br. J. Cancer 1996; 74: 650–656
   PubMed Web of Science ®Google Scholar
• Fumoleau P., Chevallier B., Kerbrat P., , et al. A Multicentre Phase II Study of the Efficacy and Safety of Docetaxel as First-Line Treatment of Advanced Breast Cancer: Report of the Clinical Screening Group of the EORTC. Ann. Oncol. 1996; 7: 165–171
   PubMed Web of Science ®Google Scholar
• Hudis C.A., Seidman A.D., Crown J.P.A., , et al. Phase II and Pharmacologic Study of Docetaxel as Initial Chemotherapy for Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 58–65
   PubMed Web of Science ®Google Scholar
• Trudeau M.E., Eisenhauer E.A., Higgins B.P., , et al. Docetaxel in Patients with Metastatic Breast Cancer: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1996; 14: 422–428
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W.W., Prove A.M., Piccart M., , et al. A Phase II Trial with Docetaxel (Taxotere) in Second-Line Treatment with Chemotherapy for Advanced Breast Cancer. A Study of the EORTC Early Clinical Trials Group. Ann. Oncol. 1994; 5: 527–532
   PubMed Web of Science ®Google Scholar
• Adachi I., Watanabe T., Takasima S., , et al. A Late Phase II Study of RP 56976 (Docetaxel) in Patients with Advanced or Recurrent Breast Cancer. Br. J. Cancer 1996; 73: 210–216
   PubMed Web of Science ®Google Scholar
• Taguchi T. An early Phase II Clinical Study of RP 56976 (Docetaxel) in Patients with Cancer of the Gastrointestinal Tract. Gan To Kagaku Ryoho 1994; 21: 2431–2437
   PubMedGoogle Scholar
• Taguchi T., Mori S., Abe R., , et al. Late Phase II Clinical Study of RP 56976 (Docetaxel) in Patients with Advanced/Recurrent Breast cancer. Gan To Kagaku Ryoho 1994; 21: 2625–2632
   PubMedGoogle Scholar
• Valero V., Holmes F.A., Walters R.S., , et al. Phase II Study of Docetaxel: A New, Highly Effective Antineoplastic Agent in the Management of Patients with Anthracycline-Resistant Metastatic Breast Cancer. J. Clin. Oncol. 1995; 13: 2886–2894
   PubMed Web of Science ®Google Scholar
• Ravdin P.M., Burris H.A., III, Cook G., III, et al. Phase II Trial of Docetaxel in Advanced Anthracycline-Resistant or Anthracenedione-Resistant Breast Cancer. J. Clin. Oncol. 1995; 13: 2879–2885
   PubMed Web of Science ®Google Scholar
• Guastalla, J.-P.; Bonneterre, J.; Fumoleau, P., et al. A Phase II Trial of Docetaxel in Patients with Anthracycline Resistant Metastatic Breast Cancer. Eur. J. Cancer 1995, 31A (Suppl. 15), 348.
   Google Scholar
• Valero V., Jones S.E., Von Hoff D.D., , et al. A Phase II Study of Docetaxel in Patients with Paclitaxel-Resistant Metastatic Breast Cancer. J. Clin. Oncol. 1998; 16: 3362–3368
   PubMed Web of Science ®Google Scholar
• Hino H., Kobayaslir K., Hayashihara K., , et al. In Vitro Combination Effect of Docetaxel (RP 56976) with Vinca Alkaloids on Cancer Cell Lines. Proc. Am. Assoc. Cancer. Res. 1995; 229
   Google Scholar
• Bissery M.C., Vrignaud P., Bayssas M., , et al. Preclinical In Vivo Activity of Docetaxel-Containing Combinations. Proc. Am. Soc. Clin. Oncol. 1995; 14: A1599
   Google Scholar
• Aoe K., Ueoka H., Kiwrak H., , et al. Synergistic Effect of Docetaxel (DCT) and Vinorelbine (VNB) Against In Vitro Growth of a Human Small-Cell Lung Cancer Cell Line. Proc. Am. Assoc. Cancer. Res. 1996; 37: A2560
   Google Scholar
• Baille P., Vernillet L., Vergniol J.C., , et al. Docetaxel (D) Pharmacokinetics (PK): Influence of Coadministered Drugs in Phase I Combination Studies. Proc. Am. Soc. Clin. Oncol. 1998; 17: 189
   Google Scholar
• Fumoleau P., Fety R., Delevioix V., , et al. Docetaxel Combined with Vinorelbine: Phase I Results and New Study Designs. Oncology 1997; 11: 29–31
   PubMedGoogle Scholar
• Ibrahim N.K., Sahin A.A., Dubrow R.A., , et al. Colitis Associated with Docetaxel-Based Chemotherapy in Patients with Metastatic Breast Cancer. Lancet 2000; 355: 281–283
   PubMed Web of Science ®Google Scholar
• Knick V., Eberweis D., Miller C.G. Vinorelbine Tartrate and Paclitaxel Combination: Enhanced Activity Against in vivo P388 Murine Leukemia Cells. J. Natl. Cancer. Inst. 1995; 87: 1072–1077
   PubMed Web of Science ®Google Scholar
• Photiou A., Shah P., Leong L.K., , et al. In Vitro Synergy of Paclitaxel (Taxol) and Vinorelbine (Navelbine) Against Human Melanoma Cell Lines. Eur. J. Cancer 1997; 33: 463–470
   PubMed Web of Science ®Google Scholar
• Galvez C., Bonamassa M., Ares S. A Phase II Trial of the Use of Docetaxel (D), Vinorelbine (VNB) in Combination with GMCSF in Taxol Refractory Metastatic Breast Cancer CMBCJ. Proc. 20th Ann. San Antonio Breast Cancer Sympos. 1997; 410
   Google Scholar
• Escudero P., Bueso P., Mayordomo J.I., , et al. Docetaxel+Vinorelbine is an Active Combination for Patients with Authracycline-Refractory Metastatic Breast Cancer. Results of a Phase II Trial. Proc. Am. Soc. Clin. Oncol. 1998; 17: 139
   Google Scholar
• Monnier A., Rioviere A., Donillard J.Y. Phase II Study of Docetaxel (Taxotere) and Vinorelbine in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Carcinoma (NSCLC). Proc. Am. Soc. Clin. Oncol. 1996; 15: 370
   Google Scholar
• Kourousis C., Kakolyris S., Androullakis N., , et al. First Line Treatment in Non-Small Cell Lung Carcinoma with Docetaxel and Vinorelbine: A Phase II Study. Proc. Am. Soc. Clin. Oncol. 1996; 15: 405
   Google Scholar
• Keidan R.D., Fanning J., Gatenby R.A., , et al. Recurrent Typhlitis, a Disease Resulting From Aggressive Chemotherapy. Dis. Colon Rectum 1989; 32: 206–209
   PubMed Web of Science ®Google Scholar
• Petalozzi B.C., Sotos G.A., Choyke P.L., , et al. Typhlitis Resulting from Treatment with Taxol and Doxorubicin in Patients with Metastatic Breast Cancer. Cancer 1993; 71: 1797–1800
   PubMed Web of Science ®Google Scholar
• Epstien M., Chiu A., Medina P., , et al. Typhlitis, Clostridia Septicum Bacteraemia, and Septic Arthritis after Treatment with Paclitaxel and Carboplatin in a Patient with non-Small Cell Lung Cancer. Cancer Ther. 1998; 1: 174–177
   Google Scholar
• Kennedy M.J., Zahurak M.L., Donehower R.C., , et al. Phase I and Pharmacologic Study of Sequences of Paclitaxel and Cyclophosphamide Supported by Granulocyte Colony-Stimulating Factor in Women with Previously Treated Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 783–791
   PubMed Web of Science ®Google Scholar